Payal Kapur1, Alana Christie2, Jay D Raman2, Matthew T Then2, Philipp Nuhn2, Alexander Buchner2, Patrick Bastian2, Christian Seitz2, Shahrokh F Shariat2, Karim Bensalah2, Nathalie Rioux-Leclercq2, Xian-Jin Xie2, Yair Lotan2, Vitaly Margulis2, James Brugarolas2. 1. Department of Pathology (PK), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Urology (PK, YL, VM), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Internal Medicine (JB), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Developmental Biology (JB), University of Texas Southwestern Medical Center, Dallas, Texas; Simmons Cancer Center (XJX, JB), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Urology, Penn State Milton S. Hershey Medical Center (JDR), Hershey, Pennsylvania; Department of Pathology, University of Pittsburgh Medical Center (MTT), Pittsburgh, Pennsylvania; Department of Urology, University of Munich (PN, AB), Munich, Germany; Department of Urology, Paracelsus-Klinik Golzheim, Dusseldorf, Germany (PB); Department of Urology, Central Hospital of Bolzano (CS), Bolzano, Italy; Department of Urology, Medical University of Vienna, Vienna General Hospital (CS, SFS), Vienna, Austria; Department of Urology and Pathology, University of Rennes (KB, NR-L), Rennes, France. Electronic address: payal.kapur@utsouthwestern.edu. 2. Department of Pathology (PK), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Urology (PK, YL, VM), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Internal Medicine (JB), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Developmental Biology (JB), University of Texas Southwestern Medical Center, Dallas, Texas; Simmons Cancer Center (XJX, JB), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Urology, Penn State Milton S. Hershey Medical Center (JDR), Hershey, Pennsylvania; Department of Pathology, University of Pittsburgh Medical Center (MTT), Pittsburgh, Pennsylvania; Department of Urology, University of Munich (PN, AB), Munich, Germany; Department of Urology, Paracelsus-Klinik Golzheim, Dusseldorf, Germany (PB); Department of Urology, Central Hospital of Bolzano (CS), Bolzano, Italy; Department of Urology, Medical University of Vienna, Vienna General Hospital (CS, SFS), Vienna, Austria; Department of Urology and Pathology, University of Rennes (KB, NR-L), Rennes, France.
Abstract
PURPOSE: Mutations in the tumor suppressor gene BAP1 occur in approximately 15% of clear cell renal cell carcinoma cases. Sequencing efforts demonstrated worse outcomes in patients with BAP1 mutated clear cell renal cell carcinoma. We investigated the clinicopathological significance and oncologic outcomes of BAP1 loss using a previously validated immunohistochemical assay. MATERIALS AND METHODS: Immunohistochemistry for BAP1 was performed on tissue microarray sections from 559 nonmetastatic clear cell renal cell carcinoma cases treated with nephrectomy at multiple institutions. The association of BAP1 expression with clinicopathological parameters was analyzed using the Wilcoxon rank sum and Cochran-Mantel-Haenszel tests. Survival was assessed by Cox regression analysis, which also identified independent predictors of time dependent outcomes. RESULTS: At a median followup of 50 months (range 0 to 183) 86 of 483 patients (17.8%) experienced recurrence and 121 of 559 (21.6%) had died. BAP1 was negative in 82 of 559 tumors (14.7%). BAP1 loss was associated with adverse clinicopathological variables, including high Fuhrman grade (p <0.0001), advanced pT stage (p = 0.0021), sarcomatoid dedifferentiation (p = 0.0001) and necrosis (p <0.0001). Cox regression revealed that patients with BAP1 negative tumors had significantly worse disease-free survival (HR 2.9, 95% CI 1.8-4.7, p <0.0001) and overall survival (HR 2.0, 95% CI 1.3-3.1, p = 0.0010) than patients with BAP1 positive tumors. CONCLUSIONS: Immunohistochemistry for BAP1 serves as a powerful marker to predict poor oncologic outcomes and adverse clinicopathological features in patients with nonmetastatic clear cell renal cell carcinoma. BAP1 assessment using immunohistochemistry on needle biopsy may benefit preoperative risk stratification and guide treatment planning in the future.
PURPOSE: Mutations in the tumor suppressor gene BAP1 occur in approximately 15% of clear cell renal cell carcinoma cases. Sequencing efforts demonstrated worse outcomes in patients with BAP1 mutated clear cell renal cell carcinoma. We investigated the clinicopathological significance and oncologic outcomes of BAP1 loss using a previously validated immunohistochemical assay. MATERIALS AND METHODS: Immunohistochemistry for BAP1 was performed on tissue microarray sections from 559 nonmetastatic clear cell renal cell carcinoma cases treated with nephrectomy at multiple institutions. The association of BAP1 expression with clinicopathological parameters was analyzed using the Wilcoxon rank sum and Cochran-Mantel-Haenszel tests. Survival was assessed by Cox regression analysis, which also identified independent predictors of time dependent outcomes. RESULTS: At a median followup of 50 months (range 0 to 183) 86 of 483 patients (17.8%) experienced recurrence and 121 of 559 (21.6%) had died. BAP1 was negative in 82 of 559 tumors (14.7%). BAP1 loss was associated with adverse clinicopathological variables, including high Fuhrman grade (p <0.0001), advanced pT stage (p = 0.0021), sarcomatoid dedifferentiation (p = 0.0001) and necrosis (p <0.0001). Cox regression revealed that patients with BAP1 negative tumors had significantly worse disease-free survival (HR 2.9, 95% CI 1.8-4.7, p <0.0001) and overall survival (HR 2.0, 95% CI 1.3-3.1, p = 0.0010) than patients with BAP1 positive tumors. CONCLUSIONS: Immunohistochemistry for BAP1 serves as a powerful marker to predict poor oncologic outcomes and adverse clinicopathological features in patients with nonmetastatic clear cell renal cell carcinoma. BAP1 assessment using immunohistochemistry on needle biopsy may benefit preoperative risk stratification and guide treatment planning in the future.
Authors: Ahmet M Aydin; Nirmish Singla; Vandana Panwar; Solomon L Woldu; Yuval Freifeld; Christopher G Wood; Jose A Karam; Alon Z Weizer; Jay D Raman; Mesut Remzi; Nathalie Rioux-Leclercq; Andrea Haitel; Marco Roscigno; Christian Bolenz; Karim Bensalah; Mary E Westerman; Arthur I Sagalowsky; Shahrokh F Shariat; Yair Lotan; Aditya Bagrodia; Payal Kapur; Vitaly Margulis; Laura-Maria Krabbe Journal: World J Urol Date: 2019-02-13 Impact factor: 4.226
Authors: N Romero-Laorden; B Doger; M Hernandez; C Hernandez; J F Rodriguez-Moreno; J Garcia-Donas Journal: Clin Transl Oncol Date: 2015-07-14 Impact factor: 3.405
Authors: Thai H Ho; Payal Kapur; Richard W Joseph; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; John C Cheville; Kevin J Wu; Eugene Frenkel; Dinesh Rakheja; Karoliina Stefanius; James Brugarolas; Alexander S Parker Journal: Urol Oncol Date: 2014-11-24 Impact factor: 3.498